BioRegenx, Inc.
BRGX
$0.0129
$0.001917.27%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -24.98% | -14.98% | -48.91% | -56.85% | 78.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.98% | -14.98% | -48.91% | -56.85% | 78.22% |
| Cost of Revenue | -48.77% | -0.30% | -46.94% | -41.99% | 93.33% |
| Gross Profit | -15.69% | -21.46% | -49.71% | -62.78% | 72.93% |
| SG&A Expenses | -91.88% | -17.09% | 212.85% | -8.21% | 311.95% |
| Depreciation & Amortization | -- | -- | -- | 0.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.70% | 25.99% | 188.08% | -13.68% | 282.36% |
| Operating Income | 86.74% | -90.93% | -1,572.68% | -42.61% | -505.64% |
| Income Before Tax | 84.32% | -86.06% | -1,271.85% | -72.26% | -443.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.32% | -86.06% | -1,271.85% | -72.26% | -443.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.32% | -86.06% | -1,271.85% | -72.26% | -443.83% |
| EBIT | 86.74% | -90.93% | -1,572.68% | -42.61% | -505.64% |
| EBITDA | 110.02% | 68.79% | -1,474.25% | -42.57% | -507.14% |
| EPS Basic | 90.24% | -50.00% | -725.00% | -70.59% | 65.83% |
| Normalized Basic EPS | 88.00% | -40.00% | -950.00% | -40.00% | 66.67% |
| EPS Diluted | 90.24% | -50.00% | -725.00% | -70.59% | 65.83% |
| Normalized Diluted EPS | 88.00% | -40.00% | -950.00% | -40.00% | 66.67% |
| Average Basic Shares Outstanding | 53.80% | 25.15% | 54.54% | 2.67% | 1,513.41% |
| Average Diluted Shares Outstanding | 53.80% | 25.15% | 54.54% | 2.67% | 1,513.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
